LNP 2.0: The Race for Organ, Tissue, and Cell-Selective LNP Delivery
Upcoming Live Webinar LNP 2.0: The Race for Organ, Tissue, and Cell-Selective LNP Delivery Lipid nanoparticles have evolved from specialized nucleic-acid carriers into clinically validated delivery platforms. Yet liver-dominant biodistribution, non-specific uptake, repeat-dose immune responses, and limited extrahepatic delivery continue to constrain broader therapeutic use. This webinar examines how LNP 2.0 is shifting the field […]
mRNA: Decoding the Future Beyond Vaccines
Self-Amplifying RNA: Redefining RNA-Based Therapeutics The global RNA therapeutics market is slated to reach $940-$950 million by 2035. Out of several promising advancements driving this growth, self-amplifying RNA therapeutics are currently leading the pack. saRNA vaccines offer protective immunity at doses that are 1,000,000-fold lower than their mRNA counterparts, with optimized platforms in preclinical models. […]
Strategic Assessment for Portfolio Expansion of an Animal Health Pharma Company
A global animal health pharmaceutical client engaged Stellarix to gain end-to-end visibility into the nsMRA landscape relevant to feline chronic kidney disease (CKD). Our actionable intelligence enabled the firm to strengthen its competitive position by expanding its portfolio, streamlining partner shortlisting & prioritizing, and identifying market gaps. Client Background: A global animal health pharmaceutical company […]
Technology Feasibility Assessment for Viral Nervous Necrosis Prevention and Management
A leading biotechnology firm engaged Stellarix for competitive benchmarking and technology feasibility assessment. Our strategic insights helped the client accelerate market readiness by identifying gaps and pinpointing scalable innovations in aquaculture, specifically supporting the development of commercial vaccines for VNN (Viral Nervous Necrosis). Client Background: A Global life sciences and biotechnology conglomerate specializing in sustainable […]
Market Assessment and Capacity Planning for Pancreatic Cancer CDMO Entry
A global Contract Development and Manufacturing Organization (CDMO) sought Stellarix’s support to assess the strategic and financial viability of pancreatic cancer-focused manufacturing devices. Our strategic intelligence enabled demand-driven capacity planning and informed market entry through effective risk mitigation and clear market visibility. Client Background: A global Contract Development and Manufacturing Organization (CDMO) intended to evaluate […]
Innovation and Partnership Scouting for Neonatology Portfolio Expansion
A world-leading biopharmaceutical company sought to expand its neonatology portfolio through strategic partnerships and early-stage technology adoption. Our strategic intelligence enabled the client to prioritize their partnership opportunities and confidently expand their portfolio. Client Background: A global, research-driven biopharmaceutical organization with a strong focus on innovation in respiratory health, rare diseases, and specialty care was […]
Will Next-Gen Neurotherapeutics Render Legacy Antidepressant Models Obsolete?
For the last three decades, Selective Serotonin Reuptake Inhibitors (SSRIs) have been the highlight of psychiatric pharmacology. However, their commercial supremacy rests on a precarious foundation – their broad-spectrum efficacy contradicts the deeply heterogeneous population of patients. This sector is now confronting an “efficacy ceiling” due to stagnating pipelines of SSRI drugs and patent cliffs […]
Improving Competitiveness of a Biopharma Leader through Psilocybin Landscape Mapping
A global biopharma leader engaged us to conduct a comprehensive therapeutic landscape assessment to expand its innovation portfolio with next-generation therapies for treatment-resistant neurological disorders. Stellarix helped the client sharpen its competitive position and innovation edge through an improved portfolio strategy and faster, data-driven decision-making. Client Background: A global biopharmaceutical company focused on central nervous […]
Mental Health Innovation: Why Psychedelic Therapies are Attracting Big Pharma?
Psychedelic therapies are witnessing an exponential surge in the mental health space. This resurgence stems from simplified or relaxed regulatory barriers, shifts in public perception, and the lack of new psychopharmacological options in the psychiatry pipeline. Additionally, rigorous scientific research on psychedelic drugs and evidence of efficacy from clinical trials are also adding to their […]
Redefining Psychiatry: Psychedelic Neurotherapeutics as a Clinical Paradigm Shift
What’s Driving the Renewed Interest in Psychedelic Medicine? The increasing acceptance of psychedelic neuro-therapeutics is changing mental health care while eliminating harm for the most difficult-to-treat malaise of our times: anxiety, depression, addiction, PTSD, etc. Encouraging early results with psychedelics like psilocybin, MDMA, and others have spurred the opening of clinics offering them, and will […]